Cat. No. 1339
Alternative Names: Arachidonylethanolamide, AEA
Chemical Name: N-(2-Hydroxyethyl)-5Z,8Z,11Z,14Z-ei
Biological ActivityEndogenous cannabinoid and TRPV1 receptor agonist (Ki values are 89 and 371 nM at CB1 and CB2 receptors respectively; EC50 values are 18, 31 and 27 nM at GPR55, CB1 and CB2 respectively; pKi = 5.68 for rTRPV1). Also blocks TNF-α-induced NF-κB activation via direct inhibition of IKK. Also available in water soluble emulsion (Cat. No. 1017) and as part of the Endocannabinoid Tocriset™.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Devane et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 1946. PMID: 1470919.
Pertwee (1999) Pharmacology of cannabinoid receptor ligands. Curr.Med.Chem. 6 635. PMID: 10469884.
Ross et al (2001) Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br.J.Pharmacol. 132 631. PMID: 11159715.
Sancho et al (2003) Anandamide inhibits nuclear factor-κB activation through a cannabinoid receptor-independent pathway. Mol.Pharmacol. 63 429. PMID: 12527815.
Ryberg et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br.J.Pharmacol. 152 1092. PMID: 17876302.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Anandamide, supplier, Endogenous, CB, receptor, agonists, vanilloids, cannabinoids, Non-Selective, Receptors, VR1, TRPV, Channels, Transient, Receptor, Potential, cb2r, cb1r, endocannabinoids, AEA